Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

NCT06356597 PHASE2 ACTIVE_NOT_RECRUITING

The aim of this study is to evaluate the efficacy and safety of Tislelizumab with Fruquintinib, Metronidazole treatment in MSS/MSI-L advanced colorectal cancer patients with high abundance of Fusobacterium nucleatum in a single arm Phase II clinical.

Details

Lead sponsor	Jing-yuan Fang, MD, Ph. D
Phase	PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	33
Start date	Fri Apr 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Dec 12 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Colorectal Cancer

Interventions

• Tislelizumab with Fruquintinib, Metronidazole

Countries

China